Genentech: Sally Fischer | Principal Scientist, BioAnalytical Sciences, Assay Development and Technology, Department of Development Sciences

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/sally-fischer

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"Genentech is an incredibly innovative and rewarding place to work. During my time here, I have had the privilege to contribute to multiple projects and have interacted with many incredibly dedicated, smart and talented scientists. I am inspired every day by knowing that our efforts in addressing unmet medical needs may have a positive impact on patient lives."

Years at Genentech

Publications

I joined Genentech in May 2000 as a Scientist contributing to the small molecule discovery effort. In 2003 I had the opportunity to join the Development Sciences department and learn about drug development. I am a Protein Scientist by training so was fascinated by our antibody therapeutic portfolio and was thrilled to be able to contribute to this effort. I am currently a Principal Scientist and Group Leader in the Assay Development and Technology group within the BioAnalytical Sciences department. The members of my team are integrated into various project teams and are responsible for development of assay strategies and methods to evaluate the pharmacokinetics (PK), anti-therapeutic antibodies as well as biomarkers to support our studies and enable filing of IND, BLA, NDA and related filings. Our focus is to provide data that will potentially enable development of novel therapeutics in both immunology and neuroscience therapeutic areas.

Featured Publication

The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies.

MAbs. 2012 Sep-Oct;4(5):623-31

Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, Song A.

View Abstract on PubMed

Data generated from a study can only be as good as the bioanalytical strategy and methods used to generate them. Development of bioanalytical methods have become increasingly more challenging with new therapeutic areas/patient populations as well as when developing novel engineered molecules. My focus is to ensure we have the right tools and strategies for our work across Genentech Research and Early Development (gRED). I lead the gIANT (gRed Immunoassay Novel Technology) forum that focuses on evaluation of novel and emerging immunoassay technologies and their implementation across gRED.

Development of a specific immunoassay to selectively measure active tryptase in airway samples

Bioanalysis, ISSN: 17576199 17576180

Gizette Sperinde; Meire Bremer; Henry Maun; Amos Baruch; Bob Lazarus; JT Koerber; Rajesh Vij; Tangsheng Yi; Sally Fischer; Tracy Staton

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Sally Fischer

Principal Scientist, BioAnalytical Sciences, Assay Development and Technology, Department of Development Sciences

Featured Publication

The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies.